Search Results

The Combined Ordinary and Extraordinary General Meeting of Transgene’s shareholders was held at 9:00 a.m. at the Company’s headquarters.

TRANSGENE announces that Management will participate in several investor events in the upcoming investor events, as set out below.

Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced that the Board of Directors has proposed Ms.

Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces its business update and its financial position for the quarter ending September 30, 2023.

Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, NEC Corporation, a leader in IT, network and AI technologies and BostonGene Corporation, a leading company in AI-based molecular and immune profiling, announced the expansion of their collaboration for the randomized Phase I/II trial of TG4050, an individualized therapeutic vaccine for patients with head and neck cancers.

Transgene, a biotech company that designs and develops virus-based immunotherapies, announced that the documentation related to the Combined General Meeting of Transgene’s shareholders is available.

TRANSGENE, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that Management will participate in several investor events, as set out below.

Transgene and BioInvent International AB announce that the first patient of the Phase I part B clinical trial evaluating the combination of BT-001 and MSD’s anti-PD-1 therapy, KEYTRUDA® has been dosed.